Gold Nanoparticles Increase Efficacy of Lung Cancer Treatments

A novel device containing gold flecks may boost the efficacy of lung cancer drugs.
 
Gold is a safe chemical element that can catalyze chemical reactions. In a new study published in Angewandte Chemie, investigators identified properties that allowed these catalytic abilities to be accessed without any adverse events. 
 
The investigators used gold nanoparticles encased in a chemical device to control these highly-specific reactions in precise locations. When implanted in zebrafish brains, the device catalyzed a directed chemical reaction, suggesting its ability to be used in living animals.
 
More importantly, the gold nanoparticles also activated anti-cancer drugs used to attack lung cancer cells in a Petri dish, ultimately increasing the drugs’ efficacy.
 
“We have discovered new properties of gold that were previously unknown and our findings suggest that the metal could be used to release drugs inside tumors very safely,” said author Dr Asier Unciti-Broceta. “There is still work to do before we can use this on patients, but this study is a step forward. We hope that a similar device in humans could one day be planted by surgeons to activate chemotherapy directly in tumors and reduce harmful effects in healthy organs.”
                                                                                                 
The method offers a novel way to modulate the activity of bioorthogonal reagents in the most fragile and complex organs, according to the authors. Furthermore, the device could be used to reduce adverse events in current chemotherapies by targeting disease cells and leaving healthy tissue unharmed.
 
“By developing new, better ways of delivering cancer drugs, studies like this have the potential to improve cancer treatment and reduce side effects,” said Dr Áine McCarthy, senior science information officer at Cancer Research UK. “In particular, it could help improve treatment for brain tumors and other hard-to-treat cancers. The next steps will be to see if this method is safe to use in people, what its long- and short-term side effects are, and if it’s a better way to treat some cancers.”
 
Roughly 450 individuals die from cancer each day in the UK, and a cancer diagnosis is made every 2 minutes.
 
 
 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Two phase 3 studies evaluating the triple combination regimen met the primary endpoint of improvement in lung function in patients with at least 1 F508del mutation.
Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.
An analysis indicates that immune-related adverse events may be more common than initially reported in the clinical trials for these therapies.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$